Trials / Recruiting
RecruitingNCT05673018
Galleri® in the Medicare Population.
REACH Study: Galleri® in the Medicare Population.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50,000 (estimated)
- Sponsor
- GRAIL, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek enrollment that is representative of the Medicare population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Multi-Cancer Early Detection Test (Galleri®) | Blood collection and multi-cancer early detection testing with return of results. |
Timeline
- Start date
- 2024-07-12
- Primary completion
- 2030-09-01
- Completion
- 2030-09-01
- First posted
- 2023-01-05
- Last updated
- 2026-02-10
Locations
47 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05673018. Inclusion in this directory is not an endorsement.